Carotid angioplasty CME promotion should await clinical trial results, clinicians say.
This article was originally published in The Gray Sheet
Executive SummaryCAROTID ANGIOPLASTY PROMOTION AT CME SYMPOSIA SHOULD AWAIT CLINICALS demonstrating the safety and effectiveness of the investigational procedure for prophylactically treating stroke, Hugh Beebe, MD, Jobst Vascular Center, Toledo, Ohio, et al. say in an editorial published in the February issue of the journal Stroke. Carotid angioplasty, with and without adjunctive stent placement, has been promoted "widely" by physicians at continuing medical education seminars sponsored by medical institutions, professional societies and manufacturers, "suggesting that it is an established procedure when in fact it is an experimental procedure," Beebe et al. state.
You may also be interested in...
The Swiss giant is hoping to get seven more approvals for its blockbuster immunology drug over the next 10 years.
Cadila has filed for approval of saroglitazar for NASH in India. The drug, which could emerge as the first medicine for the indication if approved, is already being used by a million Indian patients for diabetic dyslipidemia and hypertriglyceridemia.
It has been a long and sometimes tortuous development path for Lupuzor but ImmuPharma's chief executive tells Scrip the company's faith in the lupus drug is bearing fruit.